Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GALT
GALECTIN THERAPEUTICS INC.
NASDAQ
$4.02
▼ DOWN 2.90% (-0.12)

KEY STATISTICS

Market Cap$264.74 M
52w High$7.13
52w Low$2.03
Dividend Yield—
Frequency—
P/E-9.80
Volume271.10K
Shares Out.65.86M

COMPANY

LEADERSHIP

Joel Lewis
CHIEF EXECUTIVE
Joel Lewis

COMPENSATION 2026

Salary$620,167
Stock Awards$202,635
Incentive Plan Pay$0
All Other Comp.$54,872
Total$1,189,674

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 4, 2002
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
9

PRICE TARGET

Target High$11.00
Target Low$11.00
Target Median$11.00
Target Consensus$11.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2012-03-23Reverse1:6

PRICE

$4.02 ▼ DOWN 2.90% (−$0.12)
OVERLAYS
$3.97$4.05$4.13$4.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.02

About Galectin Therapeutics Inc.

https://galectintherapeutics.com ↗

Galectin Therapeutics Inc. is a clinical-stage biopharma developing galectin-3 inhibitors like belapectin for fibrotic, cancer, and other diseases, with lead candidates in Phase III trials for liver fibrosis and NASH cirrhosis.

INDUSTRY

Biotechnology

A PRODUCT GALECTIN THERAPEUTICS INC. IS KNOWN FOR

Belapectin (GR-MD-02)
Belapectin (GR-MD-02)

Belapectin, Galectin Therapeutics' lead drug, is a carbohydrate-based therapy targeting galectin-3, in clinical trials for MASH with cirrhosis and combined with immunotherapy for advanced melanoma and head and neck cancers.

COMPETITORS

COMPETITOR
IVA COMPARE
MDGL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
46
LISTED HERE
8
RANKED BY POSITION SIZE
VTI
0.00% · 1.5M
IWM
0.01% · 1.0M
XRS2.DE
0.01% · 43.8K
MEDX
0.99% · 42.5K
R2SC.L
0.00% · 24.0K
RSSL
0.01% · 22.7K
URTY
0.00% · 2.0K
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
22.02%
HOLDERS
153
TOP 12 OF 153 · RANKED BY POSITION SIZE
Blackrock, Inc.
3.0M sh · $13.87M
Vanguard Group Inc
2.3M sh · $9.52M
Blackrock Inc.
1.6M sh · $3.53M
Geode Capital Management, LLC
1.3M sh · $6.07M
Advisor Group Holdings, Inc.
1.2M sh · $5.24M
Marshall Wace, Llp
1.2M sh · $3.4M
Advisor Group, Inc.
799.8K sh · $2.29M
Millennium Management LLC
798.4K sh · $2.23M
Wealthspire Advisors, LLC
721.8K sh · $3.35M
State Street Corp
567.8K sh · $2.63M
Susquehanna International Group, Llp
555.7K sh · $1.55M
Two Sigma Investments, LP
467.1K sh · $1.3M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER:
Uihlein Richard E
Purchase · 31.8M shares
2026-07-31
★
DIRECTOR, 10 PERCENT OWNER:
Uihlein Richard E
Sale · —
2026-07-31
★
DIRECTOR, 10 PERCENT OWNER:
Uihlein Richard E
Purchase · 2.6M shares
2026-07-31
★
OFFICER: CHIEF MEDICAL OFFICER
Jamil Khurram
Purchase · 16.3K shares
2026-07-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
LBRX$47.73COMPARE
DRTS$14.64COMPARE
DSGN$15.11COMPARE
AURA$7.40COMPARE
ALT$3.11COMPARE
RCKT$3.86COMPARE
DMAC$6.39COMPARE
QSI$0.78COMPARE